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mary tissue failure and has potential for growth.2-5 The
use of a pulmonary autograft in young patients with
rheumatic disease is, however, still debatable.5-10
Though anecdotal cases of involvement of pulmonary
autograft in the rheumatic process have been men-
tioned,6-9 this issue remains undiscussed at large. The
present study makes an effort to analyze the suitability
of the pulmonary autograft as a substitute for the dis-
eased aortic valve in patients with rheumatic disease.
Patients and methods
From October 1993 through March 1998, 102 patients
underwent aortic valve replacement with a pulmonary auto-
graft (Ross procedure). The cause of the aortic valve lesion
was rheumatic in 75 patients (73%) and nonrheumatic in 27
patients (27%; bicuspid aortic valve in 26 patients and myxo-
matous aortoarteritis in 1 patient). The demographic profile of
patients is shown in Table I. Symptoms were dyspnea (93%),
palpitation (39%), chest pain (37%), and congestive heart fail-
S ince its first use by Ross1 in 1967, the pulmonaryautograft has been considered a well-accepted
option for aortic valve replacement. It offers the advan-
tages of central laminar flow and freedom from pros-
thetic valve complications and side effects of anticoag-
ulation.2,3 Being a viable autologous transplant, the
pulmonary autograft is characterized by absence of pri-
Background: Although pulmonary autograft is being increasingly used to
replace the diseased aortic valve with excellent long-term results, its use
in the population with rheumatiic disease still needs careful evaluation.
Patients and methods: From October 1993 through March 1998, 102
patients underwent aortic valve replacement with a pulmonary auto-
graft (Ross procedure). The mean age was 27.9 ± 4.2 years (range, 0.8-
56 years). The cause was rheumatic disease in 75 patients (73%), bicus-
pid aortic valve in 26 patients (26%), and myxomatous aortoarteritis in
1 patient (1%). The root replacement technique was used in all. In addi-
tion, 31 patients had 33 associated procedures: mitral valve repair (n =
15 patients), open mitral commissurotomy (n = 15 patients), tricuspid
repair (n = 2 patients), and homograft mitral valve replacement (n = 1
patient). Results: Operative mortality was 6.9% (7 patients). Late mor-
tality was 7.8% (8 patients). Follow-up ranged from 1 to 60 months
(mean, 25.3 ± 15.4 months) and was 98% complete. Two patients
required reoperation for failed mitral valve repair, and 2 other patients
underwent reoperation for failure of both the autograft and mitral valve
repair. Echocardiographic assessment showed moderate to severe aortic
regurgitation in 13 patients, along with thickening of the autograft. All
of these patients had rheumatic disease and were young (<30 years). Ten
of these patients had undergone associated mitral valve procedure.
Morphologic and histopathologic examination of explanted autografts
showed features compatible with rheumatic valvulitis. Conclusion:
Pulmonary autograft is susceptible to rheumatic involvement. Young
age (<30 years) and associated mitral valve disease are significant risk
factors for autograft failure in patients with rheumatic disease. Use of
pulmonary autograft in this subgroup of patients requires a cautious
approach. (J Thorac Cardiovasc Surg 1999;118:483-91)
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PULMONARY AUTOGRAFT: SHOULD IT BE USED IN YOUNG PATIENTS WITH RHEUMATIC DISEASE?
ure (69%). Most of the patients (82%) were in New York
Heart Association class III or IV. The clinical diagnosis was
severe aortic stenosis in 24 patients (24%), severe aortic
regurgitation (AR) in 53 patients (52%), and combined aortic
stenosis and AR in 25 patients (25%). In addition, patients
with rheumatic disease had associated significant mitral
stenosis (n = 16 patients), moderate to severe mitral regurgi-
tation (n = 15 patients), and severe tricuspid regurgitation
with stenosis (n = 2 patients).
Selection criteria. All patients less than 60 years of age
undergoing aortic valve replacement were offered the option
of the Ross procedure. Aortic valve replacement with a
mechanical prosthesis was performed when the patient opted
for it or when aortic root diameter was 30 mm or more. Other
exclusion criteria for the Ross procedure included associated
mitral valve disease requiring prosthetic valve replacement,
emergency operation, left ventricular dysfunction, aortopul-
monary mismatch, and bicuspid/regurgitant pulmonary valve.
The use of the pulmonary autograft in young patients with
rheumatic disease was abandoned recently as a result of our
observations.
Operative technique. Intraoperative transesophageal
echocardiography was performed for all patients. Surgical
procedures were performed under moderately hypothermic
(28°C) cardiopulmonary bypass. Antegrade cold blood car-
dioplegia (4°C) and topical cooling with ice slush was used
for myocardial protection. If required, the mitral valve proce-
dure was done first before the Ross procedure was begun.
The technique of autograft harvesting and insertion was
essentially the same as mentioned by Oury and associates11
and as described previously by us.12 After the pulmonary
artery was separated from the aorta, the pulmonary artery was
opened transversely and the pulmonary valve was inspected.
If found suitable, it was harvested and kept in the right ven-
tricular cavity for further use. The diseased aortic valve was
excised, and the right coronary ostium was separated as a but-
ton. The aortotomy incision was extended posteriorly on both
sides to meet below the left coronary ostium. Thus the aorta
was divided completely, leaving the left coronary ostium
attached to a tongue of distal aortic wall. The autograft was
inserted as in a root replacement. Proximally, the autograft
was sutured to the aortic anulus with a triangulated running
polypropylene suture. The left coronary sinus of the autograft
was slit open to within 3 to 4 mm of the cusp to receive the
tongue of the distal aorta containing the left coronary ostium.
Distal aortic anastomosis was performed with running
polypropylene suture. The right coronary button was implant-
ed in the autograft. The right ventricle–pulmonary artery con-
tinuity was re-established with either an antibiotic preserved
(n = 47 patients) or cryopreserved pulmonary/aortic homo-
graft (n = 55 patients).
In addition, 31 patients had 33 associated procedures: open
mitral commissurotomy (n = 15 patients), mitral valve repair
(n = 15 patients), tricuspid valve repair (n = 2 patients), and
homograft mitral valve replacement (n = 1 patient). The tech-
nique of mitral valve repair has been described earlier.13,14
The mean aortic crossclamp and cardiopulmonary bypass
times for the isolated Ross procedure were 119.3 ± 24.6 min-
utes (range, 84-190 minutes) and 145.8 ± 26.3 minutes
(range, 123-220 minutes), respectively. The mean ischemic
and bypass times for the Ross procedure combined with
mitral procedure were 134.3 ± 28.5 minutes (range, 110-228)
minutes) and 167.3 ± 31.4 minutes (range, 141-276 minutes),
respectively.
The autograft function was assessed intraoperatively by
transesophageal echocardiography and subsequently by
transthoracic/transesophageal echocardiography before dis-
charge from the hospital. Echocardiographic assessment was
performed subsequently at intervals of 6 months.
None of the patients with the isolated Ross procedure
received anticoagulants or antiplatelet agents. Patients who
had undergone mitral valve annuloplasty with a Teflon collar
received antiplatelet therapy for 6 months.
All patients under 45 years of age and with rheumatic
involvement were treated with antibiotic prophylaxis to pre-
vent recurrence of rheumatic fever, using long-acting benza-
thine penicillin delivered intramuscularly every 3 weeks.
Statistical analysis. For the purpose of analysis, patients
have been divided into rheumatic and nonrheumatic groups,
based on the cause of the aortic lesion. All the interval/ratio
parameters are expressed as mean ± standard deviation, and
the categoric variables are expressed as percentages. Acturial
estimates have been calculated with the Kaplan-Meier tech-
nique15 and are reported with standard error of the estimate.
Comparison of these estimates among subgroups has been
performed with the Mantel-Cox (log-rank) test.16 Prognostic
factors for late failure have been identified by Cox’s propor-
tional hazard model. All statistical analysis has been per-
formed with the SPSS for Windows 6.0 software package
(SPSS Inc, Chicago, Ill).
Results 
Early deaths. There were 7 early deaths (6.9%).
Four of the initial 12 patients died; 3 deaths were
484 Choudhary et al The Journal of Thoracic and
Cardiovascular Surgery
September 1999




0-10 — 2 2 (2%)
11-20 24 6 30 (29%)
21-30 16 5 21 (21%)
31-40 22 14 36 (36%)
41-50 11 — 11 (11%)
51-60 2 — 2 (2%)
Range (y) 11-56 0.8-40 0.8-56
Mean ± SD (y) 28.5 ± 4.3 27.4 ± 5.2 27.9 ± 4.2
Male/female 55/20 23/4 78/24
*n = 75 patients.
†n = 27 patients.
‡n = 102 patients.
attributed to excessive bleeding and its sequelae. After
a modification17 in the operative technique in the next
90 patients, there were 3 operative deaths (3.3%),
caused by myocardial dysfunction (n = 2 patients) and
ventricular arrhythmias (n = 1 patient).
Early echocardiographic results. In all patients,
intraoperative transesophageal echocardiography re-
vealed no or trivial AR. Two patients had mild (2/4+)
mitral regurgitation. Transthoracic echocardiography
performed before discharge from the hospital showed
mild (2/4+) AR in 1 patient.
Late deaths. There were 8 late deaths (7.8%). Infec-
tive endocarditis was the cause of death in 4 patients (2
patients underwent reoperation). One patient, who had
undergone associated homograft mitral valve replace-
ment, died after 6 months of mitral homograft failure.
In another patient, the initial mitral valve repair failed;
at reoperation, a partial mitral homograft replacement
was performed. However, the mitral homograft failed
and the patient died after 2 months. In an additional 2
patients (patients 1 and 13, Table II), the autograft
failed and the patients died of congestive heart failure
24 and 5 months after the operation, respectively.
Reoperation. Five patients required exploration for
excessive hemorrhage in the immediate postoperative
period. Two patients required an operation for fungal
endocarditis. Both patients died. In 2 patients, mitral
valve repair failed after 26 months and 31 months,
respectively. In the first patient, a partial mitral valve
replacement with cryopreserved homograft was per-
formed, but the patient died after 3 months. In the
other patient, the mitral valve was replaced with a
prosthetic valve. In addition, in 2 other patients
(patients 2 and 4, Table II), autograft and associated
mitral valve repair failed after 12 months and 24
months. In both the patients, aortic and mitral valves
were replaced with prosthetic valves. Both the patients
survived and are doing well after 30 months and 12
months, respectively.
Recurrent rheumatic fever. Two boys (patients 1
and 4, Table II), 11 and 13 years old, who had initially
undergone the Ross procedure associated with mitral
valve repair were admitted 8 and 12 months, respec-
tively, after the operation with acute rheumatic activity
and congestive heart failure. There was no history of
joint pains in either of the patients. Erythrocyte sedi-
mentation rate and antistreptolysin titers were raised
significantly in both the cases. Both patients had expe-
rienced the development of severe AR and moderate-
to-severe mitral regurgitation. The first patient had not
complied with penicillin prophylaxis after the opera-
tion. The second patient was receiving regular peni-
cillin prophylaxis. Both patients underwent deconges-
tion and were discharged with advice for reoperation.
Patient 1 died after 6 months; patient 4 underwent
reoperation, and both the aortic and mitral valves were
replaced with prosthetic valves.
In addition, 2 other patients (14 and 17 year olds,
male) also had a history of joint pains and fever during
their follow-up but did not have laboratory or clinical
evidence of recurrent rheumatic activity at the time of
examination.
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Table II. Demographic and clinical profile of patients with significant AR
Recurrent† Echocardiographic findings
Ross Predominant Associated rheumatic Interval‡
Patient No.* Age/sex Cause lesion procedure activity (mo) AR Cusps Root
1 11 11/M Rheumatic AR MR MV repair + 8 4/4+ Thick —
2 13 17/M Rheumatic AR MR MV repair – 48 4/4+ Thick —
3 16 23/M Rheumatic AR — – 24 3/4+ Thick Dilated
4 18 13/M Rheumatic AR MR MV repair + 12 4/4+ Thick —
5 20 22/M Rheumatic AR MS OMC – 29 3/4+ Thick —
6 29 22/M Rheumatic AR MR MV repair – 24 3/4+ Thick Dilated
7 37 14/M Rheumatic AR MR MV repair – 38 4/4+ Thick —
8 41 20/M Rheumatic AR MS OMC – 8 4/4+ Thick —
9 45 16/F Rheumatic AR MR MV repair – 30 4/4+ Thick —
10 48 21/M Rheumatic AR — – 10 4/4+ Thick —
11 61 16/M Rheumatic AR MS OMC – 18 3/4+ Thick —
12 65 18/F Rheumatic AR MR MV repair – 21 3/4+ Thick —
13 74 26/M Rheumatic AR — 12 4/4+ Thick —
MR, Mitral regurgitation; MS, mitral stenosis; OMC, open mitral commissurotomy.
*The chronologic order in which patients underwent operation.
†Recurrent rheumatic activity (diagnosed clinically or by laboratory methods).
‡The duration between the Ross procedure and the follow-up visit when significant AR was detected.
Late echocardiographic follow-up. Follow-up was
98% complete. Two patients in the rheumatic group
were lost to follow-up. The remaining 93 patients (68
in the rheumatic group; 25 in the nonrheumatic group)
underwent regular echocardiographic assessment.
Follow-up ranged from 1 to 60 months (mean, 25.3-
15.4 months).
Autograft function. In the rheumatic group, 13
patients experienced the development of moderate
(3/4+) or severe (4/4+) AR 8 to 48 months after the
operation (Fig 1). This included the 2 patients who had
recurrent rheumatic fever. In most, the significant (3-
4/4+) AR developed 12 to 24 months after the opera-
tion. Two of these patients died, and 2 of the patients
underwent reoperation. In addition, 7 other patients in
the rheumatic group experienced the development of
mild (2/4+) AR. Characteristically, all these patients
were young (<30 years of age), and 10 of them also had
multivalvular lesions at the time of the initial operation.
Demographic and clinical profiles of patients with sig-
nificant AR after operation and their echocardiograph-
ic findings are shown in Table II. 
In patients with rheumatic pathogenesis, probability
of normal autograft function without significant regur-
gitation at 60 months was 60% ± 13% (Fig 2). This was
significantly less than the expected value in patients
with nonrheumatic pathogenesis (60% vs 100%) (P =
.04). The probability of normal autograft function was
41% ± 14% in the patients with rheumatic involvement
who were less than 30 years of age. This was signifi-
cantly less than that in the patients with rheumatic
involvement who were over 30 years of age (41% vs
100%; P = .001). 
Among patients who had undergone additional mitral
valve procedures at the time of initial operation, 10
patients experienced autograft failure. The probability of
normal autograft function in patients who had undergone
an associated mitral valve procedure was 39% ± 18%,
whereas it was 93% ± 4% in those who patients who had
undergone an isolated Ross procedure (P = .002). 
In the rheumatic group, various risk factors for late
failure were analyzed separately and included age (<30
years vs >30 years), sex, chronologic order of surgery,
associated mitral disease, associated tricuspid disease,
previous cardiac procedure, and presence of congestive
heart failure. Age less than 30 years (P = .001) and
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Fig 1. Temporal occurrence of significant AR after the Ross procedure in the rheumatic group.
associated mitral valve disease (P = .04) were indepen-
dent predictors of autograft failure. The Cox propor-
tional hazard analysis was also used to predict the risk
with age as continuous variable. The hazard function
equation
h (t,xt) = h
o
(t) e–0.114 · age
yielded a hazard risk of 0.89 (95% confidence limit,
0.81-0.98), suggesting a progressive decrease in the
risk of autograft failure with advancement of age.
Mitral valve function. In the rheumatic group, 29
survivors who had undergone an associated mitral valve
procedure, 11 patients experienced significant mitral
regurgitation; 3 patients underwent mitral valve replace-
ment with a prosthetic valve, and 1 patient underwent a
partial homograft mitral valve replacement. In 1 patient,
the mitral homograft was inserted initially and failed
after an interval of 6 months, leading to death.
Homograft function. Significant right-sided homo-
graft valve dysfunction (gradient, >40 mm Hg) was
present in 3 patients. In 2 patients, gradients were
located at the distal pulmonary anastomosis; in 1
patient it was located at the level of valve. One addi-
tional patient experienced moderate pulmonary regur-
gitation. In all 4 patients, a pulmonary homograft was
used. All these patients are free of symptoms.
Morphologic features of failed autografts
Echocardiographic appearance. All the cusps of
failed autografts were thickened, and the echocardio-
graphic picture was indistinguishable from that of aor-
tic valve with chronic rheumatic regurgitation (Fig 3).
Five more patients had thickened autograft cusps
although Doppler examination showed either trivial or
mild (1-2/4+) AR. Besides cuspal thickening, in 2
patients with significant AR, the aortic root was dilated. 
Operative findings. In both the patients who under-
went reoperation for failed autograft, all 3 cusps of the
autograft were thickened and retracted and failed to
coapt. However, there was no commissural fusion or
prolapse of any of the cusps. The geometry of all the
aortic sinuses was maintained in both of the patients,
and there was no dilatation of the aortic root.
The Journal of Thoracic and
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Fig 2. The probability of freedom from significant AR after the Ross procedure (Kaplan-Meier).
Microscopic examination. Microscopic examina-
tion of explanted autograft cusps revealed valvular
thickening, fibrosis, and an active chronic inflamma-
tion with remarkable small vessel and intimal prolifer-
ation (Fig 4). The neovascularization was most marked
near the base of the cusps. The picture was compatible
with valvulitis of rheumatic involvement.
Discussion
The pulmonary autograft is considered the most suit-
able alternative for the diseased aortic valve.2-5 With the
recent reports of involvement of autograft in rheumatic
process, there is serious concern about its use in the
rheumatic population.8,9 Although in only a few cases5-9
could rheumatic involvement of the autograft be demon-
strated histopathologically at reoperation, progressive
AR in the absence of aortic root dilatation in a patient
with rheumatic heart disease strongly favors rheumatic
involvement. In both of our patients who underwent
reoperation, rheumatic valvulitis could be demonstrat-
ed. In addition, echocardiography of regurgitant auto-
grafts was indistinguishable from that of native regurgi-
tant aortic valve involved in the rheumatic process.
Besides the morphologic and histopathologic appear-
ance of regurgitant autografts, the exclusive existence of
failed autografts in the rheumatic group in our study
also suggests the rheumatic cause as a significant risk
factor for autograft failure.
What could have led to autograft failure in patients
with rheumatic conditions? Obviously, in patients
where rheumatic valvulitis was demonstrated at reoper-
ation, recurrence of the rheumatic activity was the
cause of autograft failure. In some of the reported
cases,5,6,8,9 there was history and laboratory evidence
suggesting recurrence of rheumatic fever. Two of our
patients in whom the autograft failed also had recurrent
rheumatic fever. One of these patients showed evidence
of rheumatic valvulitis at reoperation. In underdevel-
oped countries, a typical history suggestive of rheumat-
ic fever may not always be present, and the patient may
directly have features of carditis.18 This was also
observed in patient 2. The patient had demonstrable
rheumatic valvulitis at reoperation but never gave a his-
tory suggestive of rheumatic fever after the initial Ross
procedure. The involvement of the pulmonary valve in
the chronic rheumatic process is rare.19-21 Involvement
in the chronic rheumatic process appears to be related
to the mechanical force the valve faces during its
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Fig 3. Transesophageal echocardiograms show thickening of the cusps of the autograft (arrow). A, Long axis. B,
Short axis. LV, Left ventricle; AO, aorta.
A B
closed state. This is the highest in the mitral valve and
the lowest in the pulmonary valve. Somehow, when the
pulmonary autograft is transplanted to the aortic posi-
tion, it becomes susceptible to chronic rheumatic
involvement. However, when there is severe pulmonary
hypertension, the pulmonary valve is still free from
rheumatic involvement in its native position.
In 1 of the reported cases,5,6 recurrence of rheumat-
ic activity was attributed to the cessation of penicillin
prophylaxis. This was the case with 1 of our patients
also. But another 3 of our patients who received regu-
lar prophylaxis also experienced recurrent rheumatic
activity. Halees and colleagues8 have also questioned
the compliance to and efficacy of penicillin prophy-
laxis. This may be partly due to the failure of penicillin
prophylaxis as a result of higher infection rates in a
malnourished population who live in very over-crowded
conditions.18,22,23
Characteristically, among the rheumatic group, all
the patients with a failed autograft were young (<30
years of age). Because rheumatic fever is more preva-
lent in a younger population,18,22-24 this further sup-
ports the possibility of recurrent rheumatic activity in
this subgroup of patients. However, if all the failures
are related to recurrent rheumatic activity, the inci-
dence of relapse becomes unacceptably high. There
may be some other mechanism by which autografts fail
in patients with rheumatic etiology. It is possible that
pulmonary valves that appear grossly normal at opera-
tion and echocardiographically may have been affected
microscopically during recent rheumatic activity; and
when subjected to higher stress in the aortic position,
these valves develop pathologic changes and fail.
Most of the investigators have attributed the autograft
failure mainly to technical errors during the learning
curve.25,26 This does not appear to be the case in our
series. In all the patients except 1, who experienced the
development of significant AR, there was no or trivial
regurgitation at the time of discharge from the hospital.
Only 1 patient had mild AR. It was only in the subse-
quent time course that these patients experienced the
development of progressively significant AR. In our
series, autograft failure is exclusively limited to the
rheumatic population and is evenly distributed chrono-
logically. These facts suggest that technical errors dur-
ing the learning curve were not responsible for auto-
graft failure in our patients.
We have used a root replacement technique for pul-
monary autograft insertion in which a tongue of the
posterior wall of the aorta with the left main coronary
artery was left behind while the aorta was divided pos-
teriorly. This tongue of aortic wall was sutured to the
left pulmonary sinus. This technique carries a potential
risk of altering the geometry of the sinotubular junction
of the pulmonary root and may predispose to subse-
quent AR. In our experience, patients with both
rheumatic and nonrheumatic etiology had identical
technique, and thus the use of this technique could not
explain the occurrence of significant AR in the patients
with rheumatic etiology alone.
Investigators8,9 have found that preoperative AR is a
common accompaniment to subsequent autograft fail-
ure. Although, in all our patients with a failed autograft,
AR was the predominant physiologic lesion, we failed
to attach any significance to it. This may be because of
the fact that in our experience all young patients with
rheumatic pathogenesis had predominant AR.
Coexisting mitral valve pathologic feature is a seri-
ous concern in the rheumatic population. Associated
mitral valve disease that requires a surgical procedure
at the time of the initial procedure was a strong predic-
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Fig 4. A, Photomicrograph of pulmonary autograft shows
vascularization of the leaflet. There are thick- and thin-walled
blood vessels. (Hematoxylin-eosin stain; original magnifica-
tion · 400.) B, Photomicrograph of pulmonary autograft
shows thick-walled blood vessels and focal lymphomononu-
clear infiltrate within the valve leaflet. (Hematoxylin-eosin
stain; original magnification · 400.)
tor of autograft failure. Among 29 survivors who
underwent an associated mitral valve procedure, 10
patients (35%) experienced autograft failure. Similarly,
of 13 patients with a failed autograft, 10 patients (76%)
had undergone a concomitant mitral valve procedure.
The high incidence of failed mitral valve procedure in
these patients, in itself, is an important cause of mor-
bidity and reoperation and thus limits the usefulness of
the Ross procedure in this subgroup.
Considering the poor results in young patients with
rheumatic etiology (<30 years of age), we have aban-
doned the use of the Ross procedure in this subgroup of
patients. Similarly, coexisting mitral disease, usually
present in the younger subgroup, also disfavors the
Ross procedure.
We thank Mr Rajvir Singh, MSc (Stat), for statistical analy-
sis of the work.
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Commentary
Choudhary and colleagues from the All India Institute of
Medical Sciences documented a high failure rate after aortic
root replacement with pulmonary autografts in young
patients with rheumatic heart valve disease. Of 68 patients
available for follow-up, 13 patients had moderate or severe
aortic insufficiency 1 to 2 years after the operation. In addi-
tion, 5 other patients had echocardiographic evidence of
leaflet thickening, but the valve function was satisfactory at
the time of the study. The diagnosis of rheumatic disease in
the leaflets of the pulmonary autograft was confirmed at
reoperation in 2 patients. On the basis of these findings, the
authors concluded that aortic valve replacment with pul-
monary autograft might be inappropriate for young patients
with rheumatic heart disease.
Other reports have also suggested that the pulmonary valve
may become involved by the rheumatic process when trans-
ferred to the aortic position in young patients with rheumatic
involvement, particularly if they have concomitant mitral valve
disease.1,2 According to Choudhary’s study, antibiotic prophy-
laxis against recurrent streptococcal infection does not seem to
protect the pulmonary autograft from rheumatic disease.
Choudhary and colleagues had excellent results with aortic
root replacement with a pulmonary autograft in a small num-
ber of patients with bicuspid aortic valve disease. On the
basis of their findings, could we then conclude that this pro-
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cedure is bad for young patients with rheumatic aortic valve
disease but good for those patients with bicuspid aortic valve
disease? The answer is yes to the first part of the question and
no to the second for the following reasons: Young patients
with bicuspid aortic valve frequently have a dilated aortic
root as the result of premature degeneration of the media of
the aorta.3 This degenerative process also involves the media
of the pulmonary artery because both the aortic and pul-
monary roots have the same embryologic origin.3 Aortic root
replacement with pulmonary autograft in these patients
exposes the pulmonary root to systemic pressures that may
cause dilatation of the sinuses of Valsalva and sinotubular
junction.3 In the study of Choudhary and colleagues, only 2
patients with rheumatic aortic valve disease had dilatation of
the pulmonary autograft, and the authors did not mention
dilatation in patients with bicuspid aortic valve. In our expe-
rience with this operation on patients with congenital aortic
valve disease, dilatation of the pulmonary autograft is com-
mon when used for aortic root replacement.3 The freedom
from dilatation of 20% or more of the sinotubular junction at
5 years was only 30%. The technique of aortic root inclusion
was protective against dilatation of the sinuses of Valsalva and
sinotubular junction. The freedom from dilatation of the sino-
tubular junction at 5 years was 87% on patients who had the
aortic root inclusion technique. Dilatation of the sinotubular
junction increases the mechanical stress on the leaflets, which
in turn may stretch, develop fenestrations along the commis-
sures, prolapse, and cause aortic insufficiency.
Aortic valve replacement with pulmonary autograft can be
performed with various techniques. Although aortic root
replacement is the simplest and the most reproducible method,
it may not be the most appropriate method because of our
inability to predict which patients will experience the develop-
ment of dilatation of the pulmonary autograft. The techniques
of aortic root inclusion and of subcoronary implantation, albeit
more complicated, are more likely to provide lasting results.3
In the first 131 patients who survived the operation performed
by Donald Ross, 107 patients had the pulmonary autograft
implanted in the subcoronary position, and the overall freedom
from autograft failure was 75% at 20 years.4
Although aortic valve replacement with pulmonary auto-
graft was described more than 3 decades ago, it became pop-
ular only during the past decade. We no longer perform it the
way Ross described and do not know which patients are the
ideal candidates for this operation. We have learned that it is
not appropriate for young patients with rheumatic heart valve
disease and that the autograft may dilate if used for aortic root
replacement in patients with congenital aortic valve disease.
There is yet much more to be learned about this operation!
Tirone E. David, MD
Toronto, Ontario, Canada
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